TABLE 2.

Details of antibiotic treatment ^a

Variable	CMZ (n = 81)	MEM (n = 46)	P value b
Total duration of study drug, median (IQR)	8 (6–12)	9 (5–12)	0.920
Total duration of all antibiotics, median (IQR)	11 (8–14)	12 (10–16)	0.087
Empiric therapy c
None	24 (29.6%)	28 (60.9%)	0.001
AMP	1 (1.2%)	0	>0.999
SAM	8 (9.9%)	3 (6.5%)	0.745
TZP	9 (11.1%)	4 (8.7%)	0.768
CFZ	1 (1.2%)	0	>0.999
CRO	33 (40.7%)	8 (17.4%)	0.01
FEP	1 (1.2%)	1 (2.2%)	>0.999
MEM	3 (3.7%)	NA	NA
FQ d	2 (2.5%)	2 (4.3%)	0.62
Oral cephalosporin e	2 (2.5%)	0	0.534
Treatment continuation after study therapy f
Any	16 (19.8%)	24 (52.2%)	<0.001
SAM	1 (1.2%)	0	>0.999
AMC	0	1 (2.2%)	0.362
TZP	1 (1.2%)	0	>0.999
CMZ	NA	16 (34.8%)	NA
MEM	2 (2.5%)	NA	NA
FQ d	4 (4.9%)	1 (2.2%)	0.653
SXT	7 (8.6%)	1 (2.2%)	0.257
Other g	1 (1.2%)	2 (4.3%)	0.297

^a Abbreviations. AMC, amoxicillin–clavulanic acid; AMP, ampicillin; CFZ, cefazolin; CRO, ceftriaxone; FEP, cefepime; FQ, fluoroquinolone (levofloxacin, ciprofloxacin, garenoxacin); NA, not available; SAM, ampicillin–sulbactam; SXT, trimethoprim–sulfamethoxazole; TZP, piperacillin–tazobactam.

^b Bold font indicates statistically significant results (P <0.05).

^c Empiric therapy was defined as antibiotics active against Gram-negative bacteria that have been used within 96 h prior to the start of the study drug (i.e., CMZ or MEM). Four patients (three in CMZ group and one in MEM group) received two antibiotics, and both antibiotics were counted separately.

^d FQ include two levofloxacin, one ciprofloxacin, and one garenoxacin in empiric treatment, and three levofloxacin and one ciprofloxacin in treatment continuation.

^e Oral cephalosporin includes one cefditoren pivoxil and one cefcapene pivoxil.

^f Two patients (one in CMZ group and one in MEM group) received two antibiotics, and both antibiotics were counted separately for each antibiotics category.

^g Includes one patient each treated with fosfomycin and minocycline (MEM group) and one patient who received CFZ (CMZ group).